TRACT Therapeutics
Blood & Organ Banks · Illinois, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
212 W Superior St Ste 130, Chicago, Illi...Phone Number
(312) 815-8993Website
www.tracttherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 3
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
2
3
3
About TRACT Therapeutics
Singulera Therapeutics, Inc. is focused on developing a personalized regulatory T cell therapy platform, TRK-001, aimed at treating solid organ transplant patients and individuals with autoimmune disorders. The therapy utilizes patients' own regulatory T cells to establish immune tolerance, potentially preventing transplant rejection and reducing reliance on harmful immunosuppressive drugs. With significant clinical needs addressed, TRK-001 has shown early clinical success, including Orphan Drug Designation and promising results from Phase 1 trials. The company has established proprietary manufacturing methods and filed for patents in the U.S. and Europe.Explore more
TRACT Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TRACT Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once TRACT Therapeutics has new funding data
Click to see if TRACT Therapeutics had a recent Job posting/layoffs
Check out if TRACT Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on TRACT Therapeutics recently announced quarterly report
Check if TRACT Therapeutics has recently received funding, and reach out quickly before it becomes old news!
TRACT Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at TRACT Therapeutics
Product Launch: Get notified when TRACT Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined TRACT Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to TRACT Therapeutics
Compare insights from companies similar to TRACT Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TRACT Therapeutics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
TRACT Therapeutics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about TRACT Therapeutics.
TRACT Therapeutics Tech Stack
A closer look at the technologies used by TRACT Therapeutics
See more technologies
TRACT Therapeutics News & Media
TRACT Therapeutics and Taiwan Bio Therapeutics Announce Poster Presentation at American Transplant Congress 2024
CHICAGO & TAIPEI, Taiwan--(BUSINESS WIRE)--TRACT Therapeutics and Taiwan Bio Therapeutics are pleased to announce a poster presentation at the 2024 annual meeting of the American Transplant Congress (ATC) taking place June 1-5, 2024, in Philadelphia, PA. TRACT Therapeutics, a clinical-stage biotechnology company, and Taiwan Bio Therapeutics, a world-class expert in cell therapy manufacturing, formed a strategic partnership in Nov 2023 to advance a novel regulatory T cell (Treg) therapy approachTaiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant
CHICAGO & TAIPEI, Taiwan--(BUSINESS WIRE)--Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant. The partners will launch a multi-center Phase 2 clinical trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients in both the United States and Taiwan. This partnership leverages Taiwan Bio’s world-class experTriAct Therapeutics’ Novel TrxR1 Inhibitor Receives FDA Rare Pediatric Disease Designation for Treatment of Pediatric Diffuse High Grade Gliomas
TriAct Therapeutics, a private, late clinical-stage oncology therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation (RPDD) to its novel, proprietary TrxR1 inhibitor (iniparib), for the treatment of patients with pediatric diffuse high grade gliomas (pdHGG). “Receiving this rare pediatric disease designation, on top of the FDA’s [PR.com]TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001...
TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. Food and Drug Administration for the Prevention of Graft Rejection Following Solid Organ Transplantation (PRWeb November 19, 2020) Read the full story at https://www.prweb.com/releases/tract_therapeutics_inc_receives_orphan_drug_designation_for_trk_001_from_the_u_s_food_and_drug_administration/prweb17552973.htm
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TRACT Therapeutics
Sign Up For FreeTo access detailed company insights
Singulera Therapeutics, Inc. is focused on developing a personalized regulatory T cell therapy platform, TRK-001, aimed at treating solid organ transplant patients and individuals with autoimmune disorders. The therapy utilizes patients' own regulatory T cells to establish immune tolerance, potentially preventing transplant rejection and reducing r... Read More
